Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) rose 2.4% on Tuesday. The stock traded as high as C$0.45 and last traded at C$0.43. 16,606 shares were traded during trading, a decline of 80% from the average daily volume of 84,140 shares. The stock had previously closed at C$0.42.
Medicenna Therapeutics Trading Up 5.5%
The company’s 50-day moving average price is C$0.43 and its 200-day moving average price is C$0.56. The firm has a market capitalization of C$44.30 million, a PE ratio of -2.18 and a beta of 2.93. The company has a debt-to-equity ratio of 6.22, a quick ratio of 4.65 and a current ratio of 1.25.
Medicenna Therapeutics Company Profile
Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer. The Company’s most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe.
Further Reading
- Five stocks we like better than Medicenna Therapeutics
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
